The Korea Food and Drug Administration announced today (1st) that it will review the special income when it proves efficacy against 'Remdesivir', which is expected as a treatment for corona19.

If the effectiveness is confirmed in consideration of an emergency without corona19 treatment, it is a position to actively take measures to be used in patients in Korea.

According to the Ministry of Food and Drug Safety, three clinical trials of remedyvir are currently being conducted in Korea.

There are 2 clinical phase 3 trials applied by Gilead Sciences, a developer of Remdesvir, and 1 clinical trial by researchers from Seoul National University Hospital.

Gilead Science-led clinical trials are currently being conducted at the National Medical Center, Seoul Medical Center, and Kyungpook National University Hospital.

Seoul National University Hospital is conducting clinical trials in Korea in cooperation with the National Institute of Health (NIH).

The Ministry of Food and Drug Safety (KFDA) said that it is not a step to judge safety and effectiveness as a Corona 19 treatment, as clinical trials are currently underway for Remedyvir.

The recent announcement by the National Institute of Allergic and Infectious Diseases (NIAID) under the NIH in the United States that Remedyvir has been effective in treating corona19 is also a cautious position that additional data are needed.

In order to judge the effectiveness, it is necessary to comprehensively consider the number of subjects in the clinical trial, the degree of symptom expression, and adverse reactions.